Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
62.13
+0.91 (+1.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Halozyme Therapeutic
< Previous
1
2
3
4
5
6
7
Next >
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
December 07, 2021
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months.
Via
InvestorPlace
Exposures
COVID-19
Janssen's Subcutaneous Darzalex Combo Wins FDA Approval For Pretreated Multiple Myeloma
December 02, 2021
Johnson & Johnson's (NYSE: JNJ) Janssen Biotech Inc has received FDA approval for Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with...
Via
Benzinga
Exposures
Product Safety
Halozyme's Q3 Sales Boosted By Darzalex; Lifts FY21 Earnings Outlook
November 03, 2021
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q3 revenue of $115.8 million compared to $65.3 million a year ago, beating the consensus of $101.94 million....
Via
Benzinga
Halozyme Therapeutics, inc (HALO) Q3 2021 Earnings Call Transcript
November 03, 2021
HALO earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
Earnings Scheduled For May 10, 2021
May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Halozyme Stock Gains As Q2 Earnings Top Estimates On Higher Milestone, Royalty; Lifts FY21 Guidance
August 10, 2021
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q2 revenue of $136.5 million compared to $55.2 million a year ago, beating the consensus of $103.16 million....
Via
Benzinga
Halozyme Therapeutics, inc (HALO) Q2 2021 Earnings Call Transcript
August 09, 2021
HALO earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
COVID-19
Halozyme Therapeutics: Q2 Earnings Insights
August 09, 2021
Shares of Halozyme Therapeutics (NASDAQ:HALO) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 247.37% over the...
Via
Benzinga
Analyzing Halozyme Therapeutics's Unusual Options Activity
July 16, 2021
On Friday, shares of Halozyme Therapeutics (NASDAQ:HALO) saw unusual options activity. After the option alert, the stock price moved down to $42.55. Sentiment: BEARISH Option...
Via
Benzinga
Janssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma
July 12, 2021
The FDA has approved Janssen Biotech Inc's, a unit of Johnson & Johnson (NYSE: JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for multiple...
Via
Benzinga
Exposures
Product Safety
GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal
June 22, 2021
GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021
June 14, 2021
Upgrades Piper Sandler upgraded the previous rating for Boston Properties Inc (NYSE:BXP) from Neutral to Overweight. Boston Properties earned $1.56 in the first quarter,...
Via
Benzinga
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
June 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
June 07, 2021
Gainers Nymox Pharmaceutical (NASDAQ:NYMX...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2021
May 17, 2021
Upgrades B of A Securities upgraded the previous rating for Kosmos Energy Ltd (NYSE:KOS) from Neutral to Buy. In the first quarter, Kosmos Energy showed an EPS of $0.08,...
Via
Benzinga
Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript
May 10, 2021
HALO earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Earnings Outlook for Halozyme Therapeutics
May 07, 2021
On Monday, May 10, Halozyme Therapeutics (NASDAQ:HALO) will release its latest earnings report. Here is Benzinga's outlook for the company. Net Income, Earnings, And Earnings Per...
Via
Benzinga
Krystal Biotech Stock Sees Relative Strength Rating Jump To Noteworthy Territory
April 29, 2021
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. Krystal Biotech stock fits that bill.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021
May 11, 2021
Upgrades For CEVA Inc (NASDAQ:CEVA), Barclays upgraded the previous rating of Equal-Weight to Overweight. For the first quarter, CEVA had an EPS of $0.01, compared to year...
Via
Benzinga
Biotech Cel-Sci Stock Joins Rank Of Stocks With RS Ratings Over 90
April 28, 2021
Cel-Sci shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
Exposures
COVID-19
Product Safety
Biotech Applied Molecular Transport Stock Earns Relative Strength Rating Upgrade
April 27, 2021
On Tuesday, Applied Molecular Transport stock reached an important technical milestone, seeing its Relative Strength Rating jump to 91 from 87.
Via
Investor's Business Daily
Arvinas Stock Clears Technical Benchmark With 80-Plus Relative Strength Rating
April 22, 2021
Arvinas shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84.
Via
Investor's Business Daily
Scholar Rock Stock Shows Market Leadership With Healthy Jump To 83 RS Rating
April 21, 2021
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. Scholar Rock stock fits that bill.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.